Method Article

Three-Dimensional Organoids Culturing and Processing Techniques for Myometrial and Uterine Fibroids Generation

DOI:

10.3791/67568

April 30th, 2026

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This protocol outlines a manually performed technique for creating collagen-containing hydrogels embedded with 3D organoid cultures of stem cells from myometrial and uterine fibroid tissue.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Uterine fibroids are the most common benign, monoclonal, gynecological tumors in a woman's uterus. To overcome the common obstacles related to the methods used in studying these pathologies, we aimed to devise a strategy to generate three-dimensional organoid models of myometrium and uterine fibroid stem cells using collagen-containing hydrogels as embedding scaffolds. Specifically, collagen-containing hydrogels in a low attachment V-bottom 96-well plates were exploited. This method allowed the development of 3D organoids of two stem cell types from normal myometrium and uterine fibroid-containing myometrium by embedding them in collagen-containing hydrogels and forming organoids in a suitable stem cell proliferation medium. The organoids successfully differentiated, proliferated, and self-organized into complex structures, developing a sustainable system. The importance of this model is the understanding of pathophysiology and etiopathogenesis, as well as for testing new drugs to prevent or treat uterine fibroids.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Uterine fibroids, or leiomyomas, are the most common benign tumors of the uterus1. They affect a significant portion of women during their reproductive years, with research suggesting that around 77% of women experience them at some point. While many women have fibroids without symptoms, a substantial 25% experience symptoms like abnormal uterine bleeding, pelvic pain, or infertility2. The development and growth of fibroids are influenced by a variety of factors, including sex hormones, growth factors, genetic changes, and other biological mechanisms3.

In order to study pathogenesis and test drug efficacy, in vitro and animal models have been developed. Cells in 2D cultures are forced to grow on a flat surface, distorting their shape and altering their behavior compared to how they would behave in a 3D tissue environment. The major disadvantage of 2D culturing compared to 3D culturing is that it poorly represents the natural cell environment within a tissue, failing to accurately mimic complex cell-cell and cell-matrix interactions that occur in a living organism, leading to potentially inaccurate results when studying cell behavior and response to stimuli4. Additionally, UF and myometrial cells quickly lose hormone responsiveness in 2D culture5. Overall, the different animal models have provided relevant information regarding UF pathophysiology6. Compared to animal models, 3D organoids offer several advantages: they simplify experiments, are compatible with real-time imaging, and enable the study of human-specific developmental and disease aspects that are not well-represented in animal models7. On the other hand, experiments with more sophisticated animals, such as primates, are very difficult to justify ethically, in addition to high expenses8. The 3D organoid model is generally superior to the 2D cell cultures by more closely mimicking in vivo tissue architecture while being more controlled, efficient, and cost-effective than animal models. Therefore, it is essential to develop more effective alternative models that accurately replicate natural cell growth and the complexities of diseased tissue.

We aimed to set up the procedure to perform 3D culture organoids of myometrial and uterine fibroids stem cells using collagen-containing hydrogels with a manual procedure, highlighting the main advantages and limitations.

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The protocol was approved by the University of Chicago Ethnics Committee, with approval number IRB#20-1414. According to the University of Chicago's tissue bank, informed consent was obtained from all subjects from whom the tissue was collected.

1. 3D culture of organoid

  1. Culture and maintain the isolated and purified myometrial and UF Stem Cells (SC) as described previously9.
  2. Obtain SCs from liquid nitrogen and allow them to thaw. A flow chart of the culture process is shown in Figure 1.
  3. Add 5 mL of the attachment factor protein to prepare the precoated flasks. Incubate for at least 4 h at 37 °C. Then discard the excess attachment factor protein.
  4. Culture the SCs in the precoated 75 cm2 flasks using 10 mL of the medium comprising both Dulbecco's modified Eagle's medium (DMEM) and F12 supplemented with 12% fetal bovine serum (FBS). Incubate the flask in a 37 °C hypoxia incubator with an oxygen concentration of 2% until they reach 90% confluence, as shown in Figure 2A.
    NOTE: Hypoxia can play a significant role in stem cell growth, as it can promote stem cell proliferation and survival.
  5. Upon reaching confluency, detach the cells using 25% trypsin-0.1% EDTA solution in HBSS without calcium or magnesium.
    1. To do so, remove the cell culture medium. Wash the cells with 1x PBS. Add 1 mL of trypsin to one 25 cm² cell and incubate for 2-3 min.
    2. Once the cells start detaching, add medium with serum to stop the trypsin reaction. Aspirate the cell solution into a 15 mL tube and centrifuge for 5 min at 500 x g at room temperature.
    3. Carefully, discard the supernatant, leaving the pellet intact.
  6. Resuspend the cell pellet subsequently in 1 mL of serum-free stem cells proliferating medium. Disrupt any clumps through gentle pipetting.
  7. Perform cell quantification using a hemocytometer.
    1. Mix 100 µL of cell suspension with 10 µL of 0.4% Trypan Blue solution.
    2. Vortex the mixture briefly and pipette 10 µL of Trypan Blue-cell suspension into the hemocytometer chamber between the chamber notch and the glass coverslip ( Figure 2B).
    3. Count cells in boxes 1-4, use the following equations to calculate the cell count:
      Cells/mL = (total cells counted/total number of boxes counted) x dilution factor x 10,000
      Total cells in sample = cells/mL x total sample volume
  8. Mix approximately 10,000 cells with 2 µL of collagen-containing hydrogels and 98 µL of serum-free Stem cells proliferating Medium, yielding a final volume of 100 µL per well5for a V-bottom 96-well plate.
  9. Pipette 100 µL of the cell mixture into each well of a low-attachment V-bottom 96-well plate. Centrifuge at room temperature for 5 min at 100 x g.
  10. Place the plate in a 37 °C incubator with 5% CO2 for 30 min.
  11. Add an additional volume of 100 µL of serum-free Stem cells proliferating medium without collagen-containing hydrogels to each well to provide nutritional needed for the organdies to growth.
  12. Compensate for the medium evaporation by adding 10-20 µL of serum-free stem cells proliferating medium in each well in case of excessive evaporation which rarely occurs.
  13. Culture the cells for 7 days for complete growth of the organoids Figure 2C-H.Change the serum-free stem cells' proliferating medium 2x weekly (aspirating the old medium gently and then adding fresh medium) to allow culturing of SCs-derived organoids to be extended up to 21 days.

2. Frozen sectioning

  1. Collect cells from the 96-well plate in a 1.5 mL microcentrifuge tube.
  2. For cryosectioning, wash organoids 2x with Phosphate-buffered saline (PBS; 1x). Add 500 µL of PBS to the organoids, then centrifuge and discard the supernatant.
  3. Fix the organoids with 500 µL of 4% paraformaldehyde (PFA) for 60 min at 4 °C and wash again with 1x PBS.
  4. Resuspend the organoids in 100 µL of 2% methylene blue to stain for 20 min. Wash with 1x PBS and cryoprotect overnight by suspension in 500 µL of 30% sucrose.
  5. The next day, remove the sucrose solution by centrifugation. Embed the organoids in an Optimal Cutting Temperature compound (OCT) and flash-freeze at −80 °C.
  6. Section the organoids embedded in OCT using a cryostat, the optimal section depth is 10 µm, and immediately place the sections on the slides, one section per slide.
  7. Preserve the slides at 4 °C till immunofluorescence staining is performed according to the following method.
  8. Wash the slide 3x with 100 µL of 1x PBS. Then, add 100 µL of 0.1% Triton in PBS (1x) for 15 min at room temperature.
  9. Block the organoids with 5% BSA in 1x PBS for 60 min and incubate overnight with primary antibodies for Sox-2 with dilution (1:500) and α-smooth muscle actin (α-SMA) with final concentration 1 µg/mL.
  10. Wash the organoids with 100 µL of 1x PBS 3x and then incubate for 1 h in the dark with Alexa Fluor-labeled fluorescent dye secondary antibodies (1:1000).
  11. Wash with 100 µL of 1x PBS 2x then mount in Antifade Mounting Medium supplemented with DAPI (1 ng/mL).
  12. Acquire Images using a fluorescent microscope with 20x magnification. See Figure 3A and analyze the images with software for bioimaging analysis.

3. Whole-mount organoids immunofluorescence staining

  1. Remove the organoids from the media (step 1.11) into a microcentrifuge tube and wash 2x with 500 µL of 1x PBS.
  2. Fix the organoids with 500 µL of 4% PFA for 60 min at room temperature. Then discard the PFA and wash with 500 µL of PBS 3x.
  3. Permeabilize the fixed organoids with 0.5 mL of blocking buffer overnight at 4 °C.
  4. Next day, remove the blocking buffer, add primary antibodies (300-500 µL) of Collagen III (COL3A1) with dilution (1:500) and AHR with dilution (1:1000), and incubate the samples at 4 °C overnight.
  5. Wash the organoids 3x with 500 µL of 1x PBS and then incubate with secondary antibodies (594 goat anti-rabbit IgG and 488 goat anti-mouse IgG) overnight at 4 °C in the dark.
  6. Wash the organoids 3x with 500 µL of 1x PBS, then incubate with 5 µg/mL of 4′,6-diamidino-2-phenylindole (DAPI) in 1x PBS (300-500 µL per sample) at room temperature for 20 min.
  7. Wash the organoids three times with 500 µL of 1x PBS and image on a confocal microscope (Figure 3B).

4. Organoid dissociation

  1. Reconstitute 100 mg of papain in filter-sterilized activation solution to a stock concentration of 250 U/mL, incubate the solution at 37 °C for 30 min to activate the enzyme
    NOTE: It can be stored at 2 - 8 °C for up to 2 weeks.
  2. Prepare a dissociation solution (immediately before use) with 30 U/mL papain and 125 U/mL DNase I in Hanks' Balanced Salt Solution (HBSS).
  3. Transfer the organoids (step 1.11) to 24-well plates and add 500 µL of dissociation solution.
  4. Incubate the samples at 37 °C for 30- 60 min on an orbital shaker set to 90 rpm.
  5. Triturate intermittently 5x-6x using a 1 mL pipettor at room temperature to obtain a suspension consisting primarily of single cells.
  6. Add the cell suspension to a 15 mL centrifuge tube containing a protease inhibitor solution (1 mL of 10 mg/mL) and centrifuge at 300 x g for 5 min to pellet cells and discard the supernatant.
  7. Resuspend the cells in the appropriate buffer, and the resulting single-cell suspension is shown in Figure 2I.

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

As early as the first day post-seeding, SCs began to self-aggregate, forming organoids, as depicted. We determined the optimal seeding density to be 10,000 SCs, which consistently formed organoids when cultivated in a defined culture system. This system employed collagen-containing hydrogels as an ECM scaffold for the embedded stem cells and stem cell proliferation Medium for 7 days in an ultralow attachment 96-well plate Figure 2C-G. In this...

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Organoids are three-dimensional structures that resemble miniaturized organs and consist of self-organized cells derived from stem cells or tissue samples11. The patients' tissue-derived stem cell organoids have the potential to revolutionize biomedical research and clinical applications due to their remarkable ability to accurately replicate UF physiology and disease12. Here, this study attempts to bridge this gap by introducing an organoid culture system derived from huma...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors declare that they have no competing interests. The National Institutes of Health provided Dr Ayman Al-Hendy reports. Ayman Al-Hendy reported a relationship with Myovant Sciences Ltd. and Pfizer, including consulting or advisory relationships. Additionally, Dr. Ayman Al-Hendy is the founder of the INOFFA Company.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors would like to acknowledge both Erin Sullivan and Julian Romano at the University of Chicago for helping with this Video production. The authors would like to acknowledge Somayeh Vafaei, Tao Bai, Winston E. Thompson, and Qiwei Yang for helping in the the stabilization of the techniques. University of Chicago Integrated Light Microscopy Core. This study was partly supported by National Institutes of Health (NIH) grants RO1 ES028615, RO1 HD094378, U54 MD007602, RO1 HD087417, RO1 HD106285 (AAH), and Society of Endometriosis and Uterine Disorders (SUED) research grant (MA).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
2-photon confocal  MicroscopeLeica , USA
Agarose IVWR Corporation, USA97062-248
Akura 96 Spheroid Microplates InSpheroCS-09-004-03low attachment V-bottom plates
Alexa Fluor 488 goat anti mouse IgG Life Technologies, CA, USA(A11029)(1:1000)
Alexa Fluor 594 goat anti rabbit IgG Life Technologies, CA, USA(A11037)(1:1000)
Anti-Ahr [RPT] GeneTex , Taiwan(GTX227700a)(1:1000)
Anti-alpha smooth muscle Actin antibody Abcam, MA, USA(ab7817)1 µg/mL
Anti-Collagen III antibody Abcam, MA, USA(ab7778)(1:500)
Anti-SOX1 antibody Abcam, MA, USAab242125(1:500)
Attachment factor Gibco, USAS-006-100
Blocking buffer DakoX09095% horse serum + 0.5% Triton X-100 in 1X PBS
CryostatFisher Scientific, Waltham, MAMicrom HM 550
DAPI (4′,6-diamidino-2-phenylindole )Thermo Scientific, Germany622481 mg/mL
DNase IThermo-Scientific, LithuaniaEN0521
Dullbecco’s modified Eagle’s medium DMEM and  F12Gibco, USA21041-025
Fetal bovine serum Omega Scientific ,  Waltham, MANC0471611
Matrigel (collagen-containing hydrogels )Corning, Corning, NY356237
MesenCult-ACF Plus Medium (serum-free Stem cells proliferating Medium  )Stemcell Technologies, Vancouver, Canada5446
OCT compound (Optimal cutting temperature compound )Sakura, USA4583
Olympus BX41 microscope Olympus America, Center Valley, PA
Ovomucoid protease inhibitor solution Worthington Biochemical Corporation, USALK003182
Papain Worthington Biochemical Corporation, USALK003176activation solution (1.1 mM EDTA, 0.067 mM mercaptoethanol, 5.5 mM L-cysteine HCl)
PBS (Phosphate-buffered saline)Gibco, USA70011pH 7.4
PFA (paraformaldehyd) 4%Invitrogen, USAFB002
QupathBankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Scientific Reports (2017).https://doi.org/10.1038/s41598-017-17204-5software for bioimaging analysis
Time Lapse Microscope
Tissue culture flasksFisher Scientific, Waltham, MAFB012937
Trypsin Gibco, USAA12859-010.25% trypsin and 0.1% EDTA in HBSS without calcium or magnesium 
VECTASHIELD Antifade Mounting Medium supplemented with DAPIVector Laboratories, CA, USA# UX-93952-241 ng/mL

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Walker, C. L., Stewart, E. A. Uterine fibroids: the elephant in the room. Science. 308, 1589-1592 (2005).
  2. Cramer, S. F., Patel, A. The frequency of uterine leiomyomas. Am J Clin Pathol. 94, 435-438 (1990).
  3. Islam, M. S., et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 100, 178-193 (2013).
  4. Kapałczyńska, M., et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 14 (4), 910-919 (2018).
  5. Banerjee, S. Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid. Reprod Sci. 29 (9), 2607-2619 (2022).
  6. Piccini, C. D., et al. Animal models of uterine leiomyomas: a review. F S Rev. 3 (2), 121-135 (2022).
  7. Chenchula, S., Kumar, S., Babu, S., et al. Comparative Efficacy of 3Dimensional (3D) Cell Culture Organoids Vs 2Dimensional (2D) Cell Cultures Vs Experimental Animal Models In Disease modeling, Drug development, And Drug Toxicity Testing. Int J Curr Res Rev. 11 (24), 11-17 (2019).
  8. Mather, J. A. Ethics and care: For animals, not just mammals. Animals. 9, 1018(2019).
  9. Mas, A. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 104 (1), 225-234.e3 (2015).
  10. Omran, M. M., et al. Utilising Human Myometrial and Uterine Fibroid Stem Cell-Derived Three-Dimensional Organoids as a Robust Model System for Understanding the Pathophysiology of Uterine Fibroids. Cell Prolif. , e70025(2025).
  11. Kim, J., Koo, B. K., Knoblich, J. A. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 21 (10), 571-584 (2020).
  12. Yang, S., et al. Organoids: The current status and biomedical applications. MedComm. 4 (3), e274(2023).
  13. Malik, M., Catherino, W. H. Development and validation of a three-dimensional in vitro model for uterine leiomyoma and patient-matched myometrium. Fertil Steril. 97 (6), 1287-1293 (2012).
  14. Malik, M., Britten, J., Segars, J., Catherino, W. H. Leiomyoma Cells in 3-Dimensional Cultures Demonstrate an Attenuated Response to Fasudil, a Rho-Kinase Inhibitor, When Compared to 2-Dimensional Cultures. Reprod Sci. 21, 1126-1138 (2014).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Uterine FibroidsMyometrial OrganoidsThree Dimensional OrganoidsOrganoid CultureCollagen HydrogelsStem Cell ProliferationUterine Fibroid ModelsOrganoid DifferentiationDrug Testing ModelsGynecological Tumors
Video Coming Soon

Related Articles